We are live on ! Find out more
KPRX icon

Kiora Pharmaceuticals
KPRX

13 hedge funds and large institutions have $91.9K invested in Kiora Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 1

0.92% less ownership

Funds ownership: 1.16% → 0.25% (-0.92%)

24% less funds holding

Funds holding: 17 → 13 (-4)

67% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 6

78% less capital invested

Capital invested by funds: $425K → $91.9K (-$333K)

Holders
13
Holders Change
-4
Holders Change %
-23.53%
% of All Funds
0.21%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
3
Reduced
1
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors
North Carolina
+$34.1K
2
Geode Capital Management
Geode Capital Management
Massachusetts
+$21.2K
3
XT
XTX Topco
Cayman Islands
+$6.71K
4
UBS Group
UBS Group
Switzerland
+$829
5
Wells Fargo
Wells Fargo
California
+$61

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$201K
2
Walleye Capital
Walleye Capital
New York
-$162K
3
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$11K
4
HF
HRT Financial
New York
-$8K
5
TSS
Two Sigma Securities
New York
-$7.93K
Name Holding Trade Value Shares
Change 		Change in
Stake
CAPTRUST Financial Advisors
1
CAPTRUST Financial Advisors
North Carolina
$45.4K +$34.1K +6,667 +300%
Geode Capital Management
2
Geode Capital Management
Massachusetts
$21.9K +$21.2K +4,135 New
BlackRock
3
BlackRock
New York
$8.21K – – –
XT
4
XTX Topco
Cayman Islands
$6.94K +$6.71K +1,310 New
Vanguard Group
5
Vanguard Group
Pennsylvania
$5.96K – – –
TRCT
6
Tower Research Capital (TRC)
New York
$2.38K -$10 -2 -0.4%
UBS Group
7
UBS Group
Switzerland
$834 +$829 +162 +16,200%
NA
8
NewEdge Advisors
Louisiana
$114 – – –
Wells Fargo
9
Wells Fargo
California
$64 +$61 +12 +1,200%
US Bancorp
10
US Bancorp
Minnesota
$38 – – –
Osaic Holdings
11
Osaic Holdings
Arizona
$20 – – –
Morgan Stanley
12
Morgan Stanley
New York
$5 – – –
AFG
13
Albion Financial Group
Utah
$4 – – –
Fidelity Investments
14
Fidelity Investments
Massachusetts
$1 – – –
SM
15
Sabby Management
Florida
– -$201K -34,708 Closed
Walleye Capital
16
Walleye Capital
New York
– -$162K -27,806 Closed
Acadian Asset Management
17
Acadian Asset Management
Massachusetts
– -$11K -2,180 Closed
HF
18
HRT Financial
New York
– -$8K -1,497 Closed
TSS
19
Two Sigma Securities
New York
– -$7.93K -1,370 Closed
Bank of America
20
Bank of America
North Carolina
– -$3.14K -544 Closed

KPRX Hedge Fund Activity: Q3 2023 in Review

13 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Kiora Pharmaceuticals (KPRX) for Q3 2023, worth a combined $91.9K — down 78% from $425K a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of KPRX and 2 opened new positions — a net loss of 4 holders — while 1 trimmed existing stakes and 3 added.

The largest buyer was CAPTRUST Financial Advisors, adding an estimated $34.1K. The largest seller was Sabby Management, exiting entirely with an estimated $201K sold.

  • 13 institutional investors held Kiora Pharmaceuticals (KPRX) as of Q3 2023, down from 17 in Q2 2023.
  • Funds reported $91.9K of Kiora Pharmaceuticals stock for Q3 2023, down 78% quarter-over-quarter.
  • 2 funds opened new Kiora Pharmaceuticals positions in Q3 2023 and 6 closed out, a net change of -4 holders.
  • The largest Kiora Pharmaceuticals buyer in Q3 2023 was CAPTRUST Financial Advisors, an estimated $34.1K added.
  • The largest Kiora Pharmaceuticals seller in Q3 2023 was Sabby Management, an estimated $201K sold.

Based on aggregated 13F filings for Q3 2023.